Viral diseases represent a real challenge for modern medicine with the recent emergence of new viral threats worldwide such as Ebola, Dengue, Zika, Avian Influenza, Coronaviruses SARS and MERS, HIV/AIDS, and now SARS-CoV-2 / COVID-19. Ebovir is Canadian-based biotech company, mainly focused on supporting our valued customers with all viral basic research and novel biopharma therapies against viruses. We also provide Retrovirus Production Viral Expression Vectors (AAV) and viral production and purification (HSV, Vaccinia virus et al.). Our scientist board members are professors from famous Canadian universities facilitated with BSL2 and BSL3 labs. Our scientists have vast experience in virology and viral immunology. Our virology services begin with drug discovery screening (tens of antiviral models for HT drug screening) and testing programs and follows a well-defined antiviral developmental pathway, guided by documents such as the FDA Points to Consider in the Preclinical Development of Antiviral Drugs. Our services are available for the evaluation of small molecules, natural products, immune modulators, biologics and therapeutic antibodies and provide necessary support from initial discovery, structure-activity relationship evaluation, lead identification and IND-directed preclinical development. We believe that Ebovir is your right partner to make difference.